Cancer of the ovary, fallopian tube, and peritoneum

International Journal of Gynecology and Obstetrics

Volumn 119, Issue SUPPL. 2, 2012, Pages

  Berek, Jonathan S ^a   Crum, Christopher ^b   Friedlander, Michael ^c  

^a STANFORD CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CYSTECTOMY; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; DYSGERMINOMA; FEMALE; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; MIXED MULLERIAN TUMOR; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OMENTECTOMY; OVARY CANCER; OVARY CARCINOMA; OVARY SARCOMA; OVERALL SURVIVAL; PERITONEUM CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SALPINGOOOPHORECTOMY; SECOND LOOK SURGERY; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 84866651006     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/S0020-7292(12)60025-3     Document Type: Article

References (104)

1. JS Berek, M Friedlander, NF Hacker Epithelial ovarian, fallopian tube and peritoneal cancer JS Berek NF Hacker Berek and Hacker's Gynecologic Oncology 5th ed. 2009 Lippincott Williams & Wilkins Philadelphia
2. RE Scully, RH Young, PB Clements Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligaments. Atlas of Tumor Pathology. Third series 1998 Armed Forces Institute of Pathology Washington, DC
3. DW Kindelberger, Y Lee, A Miron, MS Hirsch, C Feltmate, F Medeiros et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2 2007 161 169
4. MJ Callahan, CP Crum, F Medeiros, DW Kindelberger, JA Elvin, JE Garber et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J Clin Oncol 25 25 2007 3985 3990
5. RJ Kurman, IeM Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2 2008 151 160
6. CP Crum, R Drapkin, A Miron, TA Ince, M Muto, DW Kindelberger et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 1 2007 3 9
7. JW Carlson, A Miron, EA Jarboe, MM Parast, MS Hirsch, Y Lee et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention J Clin Oncol 26 25 2008 4160 4165
8. S Aziz, G Kuperstein, B Rosen, D Cole, R Nedelcu, J McLaughlin et al. A genetic epidemiological study of carcinoma of the fallopian tube Gynecol Oncol 80 3 2001 341 345
9. K Levanon, C Crum, R Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 32 2008 5284 5293
10. X Deffieux, P Morice, A Thoury, S Camatte, P Duvillard, D Castaigne Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma J Am Coll Surg 200 1 2005 45 48
11. M Baekelandt, A Jorunn Nesbakken, GB Kristensen, CG Trope, VM Abeler Carcinoma of the fallopian tube Cancer 89 10 2000 2076 2084
12. E Burghardt, F Girardi, M Lahousen, K Tamussino, H Stettner Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer Gynecol Oncol 40 2 1991 103 106
13. CR Bankhead, ST Kehoe, J Austoker Symptoms associated with diagnosis of ovarian cancer: a systematic review BJOG 112 7 2005 857 865
14. I Lataifeh, DE Marsden, G Robertson, V Gebski, NF Hacker Presenting symptoms of epithelial ovarian cancer Aust N Z J Obstet Gynecol 45 3 2005 211 214
15. JS Berek Lymph-node positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer 19 Suppl 2 2009 S18 S20
16. RE Scully Classification of human ovarian tumors Environ Health Perspect 73 1987 15 25
17. DC Bodurka, MT Deavers, C Tian, CC Sun, A Malpica, RL Coleman et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study Cancer 118 12 2012 3087 3094
18. SE Kalloger, M Köbel, S Leung, E Mehl, D Gao, KM Marcon et al. Calculator for ovarian carcinoma subtype prediction Mod Pathol 24 4 2011 512 521
19. MH Roh, Y Yassin, A Miron, KK Mehra, M Mehrad, NM Monte et al. Highgrade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression Mod Pathol 23 10 2010 1316 1324
20. A Ayhan, RJ Kurman, A Yemelyanova, R Vang, S Logani, JD Seidman et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis Am J Surg Pathol 33 8 2009 1220 1224
21. SB Edge, DR Byrd, CC Compton, AG Fritz, FL Greene, A Trotti AJCC Cancer Staging Manual. Ovary 7th ed. 2010 Springer New York
22. R Siegel, E Ward, O Brawley, A Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 4 2011 212 236
23. A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
24. E Negri, S Franceschi, A Tzonou, M Booth, C La Vecchia, F Parazzini et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: I. Reproductive factors and risk of epithelial ovarian cancer Int J Cancer 49 1 1991 50 56
25. HT Lynch, P Watson, JF Lynch, TA Conway, M Fili Hereditary ovarian cancer. Heterogeneity in age at onset Cancer 71 2 Suppl 1993 573 581
26. JP Struewing, P Hartge, S Wacholder, SM Baker, M Berlin, M McAdams et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 20 1997 1401 1408
27. HA Risch, JR McLaughlin, DE Cole, B Rosen, L Bradley, I Fan et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 23 2006 1694 1706
28. A Chetrit, G Hirsh-Yechezkel, Y Ben-David, F Lubin, E Friedman, S Sadetzki et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 1 2008 20 25
29. F Medeiros, MG Muto, Y Lee, JA Elvin, MJ Callahan, C Feltmate et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 2 2006 230 236
30. KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng et al. ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 16 2010 1532 1543
31. U Menon, SJ Skates, S Lewis, AN Rosenthal, B Rufford, K Sibley et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer J Clin Oncol 23 31 2005 7919 7926
32. SS Buys, E Partridge, A Black, CC Johnson, L Lamerato, C Isaacs et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 22 2011 2295 2303
33. JB Trimbos, I Vergote, G Bolis, JB Vermorken, C Mangioni, C Madronal et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial J Natl Cancer Inst 95 2 2003 113 125
34. G Zanetta, S Chiari, S Rota, G Bratina, A Maneo, V Torri et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age Br J Obstet Gynaecol 104 9 1997 1030 1035
35. RC Young, LA Walton, SS Ellenberg, HD Homesley, GD Wilbanks, DG Decker et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials N Engl J Med 322 15 1990 1021 1027
36. J Bell, M Brady, J Lage, KY Look, N Spirtos, J Walker et al. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 102 3 2006 432 439
37. CM Nagle, JE Francis, AE Nelson, H Zorbas, K Luxford, A de Fazio et al. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 29 16 2011 2253 2258
38. NF Hacker, JS Berek, LD Lagasse, RK Nieberg, RM Elashoff Primary cytoreductive surgery for epithelial ovarian cancer Obstet Gynecol 61 4 1983 413 420
39. RE Bristow, RS Tomacruz, DK Armstrong, EL Trimble, FJ Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259
40. JK Chan, C Tian, GF Fleming, BJ Monk, TJ Herzog, DS Kapp et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study Gynecol Oncol 116 3 2010 301 306
41. P Benedetti Panici, A Maggioni, NF Hacker, F Landoni, S Ackermann, E Campagnutta et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer J Natl Cancer Inst 97 8 2005 560 566
42. I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 2010 943 953
43. ME van der Burg, M van Lent, M Buyse, A Kobierska, N Colombo, G Favalli et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med 332 10 1995 629 634
44. K Aabo, M Adams, P Adnitt, DS Alberts, A Athanazziou, V Barley et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group Br J Cancer 78 11 1998 1479 1487
45. PA Vasey, J Paul, A Birt, EJ Junor, NS Reed, RP Symonds et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group J Clin Oncol 17 7 1999 2069 2080
46. WP McGuire, WJ Hoskins, MF Brady, PR Kucera, EE Partridge, KY Look et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 1996 1 6
47. RF Ozols, BN Bundy, B Greer, BE Greer, JM Fowler, D Clarke-Pearson et al. Phase III trial of carboplatin and paclitaxel compared cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 17 2003 3194 3200
48. M Gemignani, M Hensley, R Cohen, E Venkatraman, PE Saigo, RR Barakat Paclitaxel-based chemotherapy in carcinoma of the fallopian tube Gynecol Oncol 80 1 2001 16 20
49. MA Bookman, MF Brady, WP McGuire, PG Harper, DS Alberts, M Friedlander et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer InterGroup J Clin Oncol 27 9 2009 1419 1425
50. M Markman, PY Liu, S Wilczynski, B Monk, LJ Copeland, RD Alvarez et al. Phase III randomized trial of 12 versus 3 months of maintenance after paclitaxel in patients with advanced ovarian cancer complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 13 2003 2460 2465
51. AH Calvert, DR Newell, LA Gumbrell, S O'Reilly, M Burnell, FE Boxall et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 11 1989 1748 1756
52. S Nagao, K Fujiwara, N Imafuku, R Kagawa, Y Kozuka, T Oda et al. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula Gynecol Oncol 99 2 2005 327 333
53. DS Alberts, PY Liu, EV Hannigan, R O'Toole, SD Williams, JA Young et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 26 1996 1950 1955
54. M Markman, BN Bundy, DS Alberts, JM Fowler, DL Clark-Pearson, LF Carson et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian cancer: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and the Eastern Cooperative Oncology Group J Clin Oncol 19 4 2001 1001 1007
55. DK Armstrong, B Bundy, L Wenzel, HQ Huang, R Baergen, S Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 1 2006 34 43
56. JL Walker, DK Armstrong, HQ Huang, J Fowler, K Webster, RA Burger et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study Gynecol Oncol 100 1 2006 27 32
57. K Jaaback, N Johnson Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Cochrane Database Syst Rev 1 2006 CD005340
58. N Katsumata, M Yasuda, F Takahashi, S Isonishi, T Jobo, D Aoki et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 9698 2009 1331 1338
59. TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, G Kristensen et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
60. RA Burger, MF Brady, MA Bookman, GF Fleming, BJ Monk, H Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
61. SC Dowdy, CL Constaninou, LC Hartman, GL Keeney, VJ Suman, DW Hillman et al. Longterm follow-up of women with ovarian cancer after positive second-look laparotomy Gynecol Oncol 91 3 2003 563 568
62. EH Tay, PT Grant, V Gebski, NF Hacker Secondary cytoreductive surgery for recurrent epithelial ovarian cancer Obstet Gynecol 99 6 2002 1008 1013
63. DS Chi, K McCaughty, JP Diaz, J Huh, S Schwabenbauer, AJ Hummer et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 9 2006 1933 1939
64. GJ Rustin, ME van der Burg, CL Griffin, D Guthrie, A Lamont, GC Jayson et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 9747 2010 1155 1163
65. M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 3 1991 389 393
66. E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, P Harter et al. Clinical trials in recurrent ovarian cancer Int J Gynecol Cancer 21 4 2011 771 775
67. MK Parmar, JA Ledermann, N Colombo, A du Bois, JF Delaloye, GB Kristensen et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
68. J Pfisterer, I Vergote, A du Bois, E Eisenhauer, AGO-OVAR, NCIC CTG, EORTC GCG Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer Int J Gynecol Cancer 15 Suppl 1 2005 36 41
69. J Pfisterer, JA Ledermann Management of platinum-sensitive recurrent ovarian cancer Semin Oncol 33 2 Suppl 6 2006 S12 S16
70. C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 2012 2039 2045
71. AN Gordon, JT Fleagle, D Guthrie, DE Parkin, ME Gore, AJ Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 14 2001 3312 3322
72. PJ Hoskins, KD Swenerton Oral etoposide is active against platinum-resistant epithelial ovarian cancer J Clin Oncol 12 1 1994 60 63
73. PG Rose, JA Blessing, AR Mayer, HD Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 16 2 1998 405 410
74. M Friedlander, MJ Millward, D Bell, R Bugat, P Harnett, JA Moreno et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer Ann Oncol 9 12 1998 1343 1345
75. JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol Oncol 63 1 1996 89 93
76. C Williams, I Simera, A Bryant Tamoxifen for relapse of ovarian cancer Cochrane Database Syst Rev 3 2010 CD001034
77. JA Hurteau, MF Brady, KM Darcy, WP McGuire, P Edmonds, ML Pearl et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group Study Gynecol Oncol 119 3 2010 444 450
78. P Butow, M Stockler, C Gainford, J Martyn, A Oza, HS Donovan et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer Int J Gynecol Cancer 19 Suppl 2 2009 S44 S48
79. N Lalwani, AK Shanbhogue, R Vikram, A Nagar, J Jagirdar, SR Prasad Current update on borderline ovarian neoplasms AJR Am J Roentgenol 194 2 2010 330 336
80. AW Kennedy, WR Hart Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma Cancer 78 2 1996 278 286
81. P Morice, D Denschlag, A Rodolakis, N Reed, A Schneider, V Kesic et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors Int J Gynecol Cancer 21 5 2011 951 963
82. KK Shih, QC Zhou, C Aghajanian, J Huh, RA Soslow, JC Morgan et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors Gynecol Oncol 119 2 2010 270 273
83. G Zanetta, S Rota, S Chiari, C Bonazzi, G Bratina, C Mangioni Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study J Clin Oncol 19 10 2001 2658 2664
84. N Colombo, G Parma, V Zanagnolo, A Insinga Management of ovarian stromal cell tumors J Clin Oncol 25 20 2007 2944 2951
85. ST Schumer, SA Cannistra Granulosa cell tumors of the ovary J Clin Oncol 21 6 2003 1180 1189
86. P Pautier, M Gutierrez-Bonnaire, A Rey, I Sillet-Bach, C Chevreau, P Kerbrat et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors Int J Gynecol Cancer 18 3 2008 446 452
87. J Brown, HS Shvartsman, MT Deavers, LM Ramondetta, TW Burke, MF Munsell et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors Gynecol Oncol 97 2 2005 489 496
88. C Winter, P Albers Testicular germ cell tumors: pathogenesis, diagnosis and treatment Nat Rev Endocrinol 7 1 2011 43 53
89. GV Kondagunta, RJ Motzer Chemotherapy for advanced germ cell tumors J Clin Oncol 24 35 2006 5493 5502
90. S Williams, JA Blessing, SY Liao, H Ball, P Hanjani Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group J Clin Oncol 12 4 1994 701 706
91. SD Williams, JA Blessing, KD Hatch, HD Homesley Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group J Clin Oncol 9 11 1991 1950 1955
92. DM Gershenson, M Morris, A Cangir, JJ Kavanagh, CA Stringer, CL Edwards Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin J Clin Oncol 8 4 1990 715 720
93. SD Williams, JA Blessing, PJ DiSaia, FJ Major, HG Ball 3rd, SY Liao Second-look laparotomy in ovarian germ cell tumors: the Gynecologic Oncology Group experience Gynecol Oncol 52 3 1994 287 291
94. PC Wu, RL Huang, JH Lang, HF Huang, LJ Lian, MY Tang Treatment of malignant ovarian germ cell tumors with preservation of fertility: a report of 28 cases Gynecol Oncol 40 1 1991 2 6
95. G Zanetta, C Bonazzi, M Cantu, S Binidagger, A Locatelli, G Bratina et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors J Clin Oncol 19 4 2001 1015 1020
96. AC Casey, S Bhodauria, A Shapter, R Nieberg, JS Berek, R Farias-Eisner Dysgerminoma: the role of conservative surgery Gynecol Oncol 63 3 1996 352 357
97. JJ Low, LC Perrin, AJ Crandon, NF Hacker Conservative surgery to preserve ovarian function in patients with malignant germ cell tumors. A review of 74 cases Cancer 89 2 2000 391 398
98. GK Mathew, SS Singh, RG Swaminathan, SG Tenali Laparotomy for post chemotherapy residue in ovarian germ cell tumors J Postgrad Med 52 4 2006 262 265
99. DM Patterson, N Murugaesu, L Holden, MJ Seckl, GJ Rustin A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites Int J Gynecol Cancer 18 1 2008 43 50
100. GG Dark, M Bower, ES Newlands, F Paradinas, GJ Rustin Surveillance policy for stage I ovarian germ cell tumors J Clin Oncol 15 2 1997 620 624
101. RA Huddart, G Purkalne, ESMO Guidelines Task Force ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT) Ann Oncol 16 Suppl 1 2005 i37 i39
102. JS Berek, M Friedlander, NF Hacker Germ cell and other nonepithelial ovarian cancers JS Berek NF Hacker Berek and Hacker's Gynecologic Oncology 5th ed. 2009 Lippincott Williams & Wilkins Philadelphia 509 535
103. T Le, GV Krepart, RJ Lotocki, MS Heywood Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience Gynecol Oncol 65 2 1997 237 240
104. AK Sood, JI Sorosky, MS Gelder, RE Buller, B Anderson, EJ Wilkinson et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction Cancer 82 9 1998 1731 1737